StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.06+0.02 (+1.92%)

Close on Nov 17, 2026Market cap $106.36MP/E –Yield –

Cellectis price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Cellectis's price to sales ratio was 1.9× on Nov 11, 2026, against 12.3× a year earlier. Over the last 5 years it ranged from 1.5× to 76.5×, with a median of 5.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.9×−9.8
2025Dec 31, 202511.7×+4.6
2024Jan 31, 20247.1×−0.2
2023Dec 29, 20237.3×+4.2
2022Dec 30, 20223.1×−4.1
2021Dec 31, 20217.2×−68.5
2020Dec 31, 202075.7×+18.6
2019Dec 31, 201957.1×+33.3
2018Dec 31, 201823.8×+0.8
2017Dec 29, 201723.0×+12.3
2016Dec 30, 201610.7×–

More Cellectis figures

See a number that looks wrong?